<- Go Home
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Market Cap
INR 1.0T
Volume
78.3K
Cash and Equivalents
INR 9.9B
EBITDA
INR 88.7B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
INR 193.1B
Profit Margin
56.43%
52 Week High
INR 1.4K
52 Week Low
INR 1.0K
Dividend
0.64%
Price / Book Value
2.89
Price / Earnings
17.71
Price / Tangible Book Value
4.23
Enterprise Value
INR 1.0T
Enterprise Value / EBITDA
11.42
Operating Income
INR 70.8B
Return on Equity
17.36%
Return on Assets
8.78
Cash and Short Term Investments
INR 69.8B
Debt
INR 58.5B
Equity
INR 362.1B
Revenue
INR 342.1B
Unlevered FCF
INR 15.6B
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium